Dark Matter Blog

AUGUST 27, 2020

A few years ago, at Arrakis Therapeutics, we set out to conquer a strange new territory, drugging RNA structures with small molecules. On the strength of those findings, nusinersen was approved by the FDA at the end of 2016 for the treatment of SMA , marketed under the commercial brand Spinraza.

Small Molecule 52

Small Molecule RNA Clinical Trials Drugs 52

Metabolite Tales Blog

APRIL 4, 2023

Metabolism of 2022 FDA approved small molecule drugs part 2 Mixing it Up By Julia Shanu-Wilson In Part 1 of this topic we looked at metabolism of the small molecule drugs approved by the FDA in 2022 that were mediated by CYP3A4. Oxidation of adagrasib occurs on the methylpyrrolidine group 4.

Small Molecule 52

Small Molecule FDA Approval FDA Drugs 52

Metabolite Tales Blog

JANUARY 23, 2024

Metabolism of 2023 FDA Approved Small Molecules – PART 1 By Julia Shanu-Wilson 2023 was a fruitful year for drug approvals by the FDA, with a crop of 34 small molecules out of a total of 55 new drugs [1]. Enzymes involved include CYP1A2, CYP2C8, CYP3A4, CYP4F2, and aldehyde oxidase (AOX).

Small Molecule 52

Small Molecule FDA Approval FDA Pharmacokinetics 52

Drug Target Review

DECEMBER 13, 2024

These types differ in their etiology, natural history, and present distinct challenges in disease management. 2 Unmet needs in lung cancer treatment Recent decades have seen significant advancements in lung cancer treatment, especially with the introduction of targeted therapies and immunotherapies, which have notably improved survival rates.

Therapies 98

Therapies Treatment Clinical Trials Drugs 98

ASPET

OCTOBER 12, 2023

Supramolecular nanostructured based delivery systems are emerging as a meaningful approach in treatment of cancer, offering controlled drug release and improved therapeutic efficacy. Different SNs approaches and recent literature reviews on peptide delivery are also presented to the readers.

Therapies 100

Therapies Small Molecule Treatment Drugs 100

The Pharma Data

JULY 29, 2021

Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Kumquat Biosciences today announced an exclusive collaboration focused on the discovery, development and commercialization of potential novel small molecules that stimulate tumor-specific immune responses.

Small Molecule 52

Small Molecule Immune Response Research Laboratories Laboratories 52

DrugBank

JULY 24, 2024

These multifunctional small molecules are like tiny spies, hijacking the body’s natural protein degradation system to remove unwanted proteins. Similarly, PROTACs can target and degrade overexpressed proteins, offering a way to overcome drug resistance, a common issue in cancer treatment.

Small Molecule 98

Small Molecule Drugs Clinical Trials Therapies 98

Chemical Biology and Drug Design

JUNE 7, 2023

In the present study, we got the SIRT7 protein structure from Alpha Fold2 Database and performed structure-based virtual screening to develop specific SIRT7 inhibitors using the SIRT7 inhibitor 97,491 interaction mechanism. In our study, we demonstrated that targeting SIRT7 may offer novel therapeutic options for cancer treatment.

Small Molecule 100

Small Molecule Treatment Research 100

Drug Target Review

SEPTEMBER 25, 2024

4 Another related and well described non-oncogene resistance mechanism is the histological transformation of EGFR-mutated non-small cell lung cancer (NSCLC) to small-cell lung cancer upon treatment with an EGFR inhibitor. This orally available small molecule binds to the bromodomain of CBP/p300 in a highly specific manner.

Small Molecule 105

Small Molecule Therapies Regulations Treatment 105

Chemical Biology and Drug Design

MAY 11, 2023

Abstract Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising therapeutic target for the treatment of hyperlipidemia. In discovery of novel small molecules that interfere PCSK9/LDLR protein–protein interaction (PPI), structural modification was performed based on our previously derived compounds.

Small Molecule 100

Small Molecule Treatment Research 100

Drug Target Review

APRIL 7, 2025

Advancements in screening technologies for small-molecule drug discovery including cellular assays, computational screening, and biophysics-based methods enhanced by structural biology breakthroughs have improved screening hit rates and facilitated the identification of drug candidates for previously undruggable targets.

Fragment Screening 52

Fragment Screening Drugs Small Molecule Biophysical Assays 52

Drug Target Review

JULY 12, 2023

Molecular-level biochemical assays like transcriptomics, genomics and proteomics have emerged as valuable tools for identifying potential targets in cancer treatment through deep cyclic inhibition (DCI). How does the DCI mechanism compare to the design of other drugs for cancer treatment?

Biochemical Assays 98

Biochemical Assays Treatment Bioinformatics Disease 98

DrugBank

MAY 22, 2024

In the dynamic world of drug discovery, the notion of "undruggable" targets presents both a significant challenge and an intriguing frontier for researchers and pharmaceutical companies. Many cancer treatments target DNA, but often these can cause collateral damage, leading to severe side effects.

Small Molecule 96

Small Molecule RNA DNA Pharmaceutical Companies 96

Drug Target Review

OCTOBER 4, 2023

Antibody-drug conjugates (ADCs) have been a groundbreaking approach to cancer treatment with their ability to deliver cytotoxic drugs directly to diseased cells while sparing healthy tissues. Groundbreaking strategies like proteolysis-targeting chimeric molecules (PROTACs) are also being explored.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

Drug Target Review

AUGUST 25, 2023

What makes RRx-001 a first-in-class hypoxia-activated therapeutic, and how does its dual mechanism of action differ from traditional cancer treatments? Most, if not all, traditional cancer treatments are single minded.

Small Molecule 98

Small Molecule Virus International Clinical Trials 98

The Pharma Data

NOVEMBER 11, 2020

Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for SLV213 for the treatment of COVID-19 and has dosed the first subjects in a Phase 1 clinical study. SLV213 is a novel, orally available, small molecule antiviral drug candidate that inhibits human host cell cysteine proteases to block viral entry.

Treatment 52

Treatment Small Molecule Virus Pharmacokinetics 52

The Pharma Data

NOVEMBER 18, 2020

Presentations to highlight the OBI-833 Phase 1 clinical study results in non-small cell lung cancer (NSCLC) and the dose escalation cohort. These results will be presented by the lead investigators of OBI Pharma’s novel anti-Globo H therapeutic cancer vaccine, OBI-833. ” Presentation number: 397P / Poster: ID 680.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

Drug Target Review

APRIL 16, 2024

Can you explain how Radioligand Therapy (RLT) is applicable in the treatment of both chemotherapy-resistant tumours and in naïve patients who have not undergone prior cancer treatment? RLT utilises radiopharmaceuticals, which are compounds consisting of a targeting molecule (ligand) and a radioactive isotope (radionuclide).

Small Molecule 59

Small Molecule Therapies Treatment Pharmaceutical Companies 59

The Pharma Data

OCTOBER 26, 2020

(Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the Company will present at the ROTH Capital Partners 2020 MedTech Innovation Forum on Wednesday, October 28, 2020. About Aridis Pharmaceuticals, Inc.

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

The Pharma Data

SEPTEMBER 2, 2020

New data further reinforce OCREVUS (ocrelizumab) as a highly effective treatment option offering a favourable and consistent benefit:risk profile, with high treatment persistence and adherence. Initiation of Phase IIIb OCREVUS higher dose clinical trial programme and Phase IV study evaluating OCREVUS in minority populations.

Clinical Trials 52

Clinical Trials Disease Treatment Therapies 52

Drug Target Review

MARCH 1, 2024

How significant are the results in terms of advancing TCR-T cell therapy and AMP immunotherapy for the treatment of solid tumours? Long-term protection against tumour recurrence in AMP-treated mice was associated with antigen spreading to additional tumour-associated antigens not targeted by the treatment.

Immune Response 105

Immune Response Therapies Vaccine Small Molecule 105

The Pharma Data

APRIL 11, 2023

Bayer is progressing novel research around its prostate cancer treatment darolutamide. The presentation highlights the synergistic anti-cancer effects of a PSMA (prostate-specific membrane antigen)-actinium-225 conjugate in combination with darolutamide in preclinical prostate cancer models.

Research 40

Research Clinical Trials Small Molecule Trials 40

Alta Sciences

APRIL 17, 2024

Five Promising Treatment Areas in Early-Phase Drug Development in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues.

Drug Development 52

Drug Development Treatment FDA Approval Drugs 52

The Pharma Data

JANUARY 10, 2021

SH ) submitted its pivotal phase III clinical trial application (IND) of national class I innovative drug Chiauranib to NMPA, for the treatment of Small Cell Lung Cancer (SCLC) as a single agent for the patients after 2nd-line systemic chemotherapy and recurrence afterwards. (Chipscreen Biosciences, Stock Symbol: 688321.SH

Clinical Trials 52

Clinical Trials Treatment Trials Small Molecule 52

The Pharma Data

APRIL 6, 2021

Bayer will present new research across its oncology portfolio at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021 , taking place over two weeks on April 10-15 and May 17-21, 2021. This includes preclinical data on darolutamide analyzing the impact of androgen stimulation and darolutamide treatment.

Research 52

Research Small Molecule Treatment Clinical Trials 52

The Pharma Data

DECEMBER 5, 2020

The data is being presented today in oral presentations at the 62nd American Society of Hematology (ASH) Annual Meeting. The new data presented today strengthen our conviction that SY-1425 has the potential to become the foundation of care for all RARA-positive patients,” said David A. Chief Medical Officer of Syros.

Clinical Trials 52

Clinical Trials Trials Small Molecule Treatment 52

The Pharma Data

JANUARY 13, 2021

These Phase 2 results strongly support the continued development of dexpramipexole as a potential first-in-class oral agent for the treatment of eosinophilic asthma,” said Michael Bozik, M.D., Knopp expects to present results of the trial at a forthcoming medical meeting. Measuring Eosinophils to Make Treatment Decisions in Asthma.

Trials 52

Trials Small Molecule Clinical Trials Treatment 52

The Pharma Data

DECEMBER 21, 2020

21 December 2020 — AstraZeneca’s Tagrisso ( osimertinib ) has been approved in the US for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after tumour resection with curative intent. 0.23; p<0.0001).

Treatment 52

Treatment Trials Disease FDA 52

The Pharma Data

SEPTEMBER 28, 2020

The product, known as INNA-051, is a synthetic small molecule therapy, self-administered once or twice weekly with an almost immediate effect. We’ve been amazed with just how effective our treatment has been. If humans respond in a similar way, the benefits of treatment are two-fold.

Immune Response 52

Immune Response Small Molecule Virus Vaccine 52

New Drug Approvals

SEPTEMBER 29, 2024

link] 01 Aug 2022 Cortexyme is now called Quince Therapeutics You need to be a logged in or subscribed to view this content This small molecule is an orally available protease inhibitor targeting the lysine proteases of the periodontal pathogen Porphyromonas gingivalis. gingivalis is associated with cardiovascular disease. and Europe.

Small Molecule 62

Small Molecule DNA Disease Trials 62

DrugBank

AUGUST 15, 2024

Financial Implications of High-Level Industry-Academic Collaborations Accelerated Time-to-Market The traditional drug development timeline, which can span over a decade, is a significant obstacle to delivering timely treatments to patients. Past collaborations have already yielded three clinical oncology candidates. One

Drug Development 98

Drug Development Clinical Trials Drugs Therapies 98

Drug Target Review

JULY 7, 2023

In pregnant individuals, maternal autoantibodies can even attack the organs and tissues of the foetus, 1-9 Many of these diseases are rare, with no safe, targeted, advanced and effective treatment options approved for patients in need. By stopping or blocking the normal work of these molecules, diseases can often be slowed or even stopped.

Disease 98

Disease Immune Response Therapies Treatment 98

The Pharma Data

DECEMBER 15, 2020

However, natural product drug discovery presents several challenges that have reduced industry interest, including the inability to identify and isolate novel bioactive molecules responsible for a desired effect. Natural products have yielded numerous landmark drugs including aspirin, metformin, morphine and quinine.

Small Molecule 52

Small Molecule Production Laboratories Engineering 52

Nvidia Developer: Drug Discovery

DECEMBER 19, 2023

HiFi-NN results compared to SoTA models in Enzyme Functional Annotation on the price-149 enzyme benchmarking dataset Developed in collaboration with advisors Noelia Ferruz and Kevin Yang, HiFi-NN was accepted by NeurIPS, a prestigious AI conference, for presentation at their Machine Learning for Structural Biology workshop in December 2023.

Science 102

Science Small Molecule Bioinformatics Research 102

The Pharma Data

MAY 16, 2022

AbbVie (NYSE: ABBV) today announced that 27 abstracts across its gastroenterology portfolio will be presented at the Digestive Disease Week (DDW) Annual Meeting, May 21-24, 2022, in San Diego and virtually. “We are proud to present data on a range of digestive conditions across our portfolio and pipeline. .

Disease 40

Disease Small Molecule Treatment Trials 40

The Pharma Data

JANUARY 10, 2021

IDE397 program update to be presented at the 39th Annual J.P. IDEAYA Biosciences will present a program update on IDE397 and its broader synthetic lethality pipeline at the 39 th Annual J.P. IDEAYA’s presentation for the 39 th Annual J.P. SOUTH SAN FRANCISCO, Calif. , Morgan Healthcare Conference.

FDA 52

FDA Clinical Trials Small Molecule Therapies 52

Metabolite Tales Blog

DECEMBER 13, 2023

Conjugation of small molecule drugs to glucuronic acid is catalysed by several UGTs to frequently form N – and O -glucuronides. As in this example, most N -glucuronides of small molecule drugs are innocuous and possess no pharmacological activity.

Small Molecule 59

Small Molecule Metabolic Stability Treatment Drugs 59